// prisma/seeds/seed-cdss.ts
// =====================================================================
// Ø¨ÙŠØ§Ù†Ø§Øª Ø£ÙˆÙ„ÙŠØ© Ù„Ù†Ø¸Ø§Ù… Ø¯Ø¹Ù… Ø§Ù„Ù‚Ø±Ø§Ø± Ø§Ù„Ø³Ø±ÙŠØ±ÙŠ
// Ø§Ù„ØªÙØ§Ø¹Ù„Ø§Øª Ø§Ù„Ø¯ÙˆØ§Ø¦ÙŠØ© Ø§Ù„Ø´Ø§Ø¦Ø¹Ø© - Ø§Ù„Ù…ØµØ¯Ø±: FDA, Micromedex, BNF
// =====================================================================

import { PrismaClient, DrugInteractionSeverity } from '@prisma/client';

const prisma = new PrismaClient();

// ======================== Ø§Ù„ØªÙØ§Ø¹Ù„Ø§Øª Ø§Ù„Ø¯ÙˆØ§Ø¦ÙŠØ© Ø§Ù„Ø´Ø§Ø¦Ø¹Ø© ========================

const DRUG_INTERACTIONS = [
  // ============ Ù…Ù…ÙŠØ¹Ø§Øª Ø§Ù„Ø¯Ù… (Anticoagulants) ============
  {
    drugAGeneric: 'warfarin',
    drugBGeneric: 'aspirin',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Increased risk of bleeding. Concurrent use should be avoided or monitored closely.',
    descriptionAr: 'Ø²ÙŠØ§Ø¯Ø© Ø®Ø·Ø± Ø§Ù„Ù†Ø²ÙŠÙ. ÙŠØ¬Ø¨ ØªØ¬Ù†Ø¨ Ø§Ù„Ø§Ø³ØªØ®Ø¯Ø§Ù… Ø§Ù„Ù…ØªØ²Ø§Ù…Ù† Ø£Ùˆ Ø§Ù„Ù…Ø±Ø§Ù‚Ø¨Ø© Ø§Ù„Ø¯Ù‚ÙŠÙ‚Ø©.',
    recommendation: 'Monitor INR closely. Consider alternative antiplatelet if needed.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'warfarin',
    drugBGeneric: 'ibuprofen',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Increased risk of gastrointestinal bleeding.',
    descriptionAr: 'Ø²ÙŠØ§Ø¯Ø© Ø®Ø·Ø± Ø§Ù„Ù†Ø²ÙŠÙ Ø§Ù„Ù‡Ø¶Ù…ÙŠ.',
    recommendation: 'Avoid combination. Use acetaminophen for pain if possible.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'warfarin',
    drugBGeneric: 'naproxen',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'NSAIDs increase warfarin effect and bleeding risk.',
    descriptionAr: 'Ù…Ø¶Ø§Ø¯Ø§Øª Ø§Ù„Ø§Ù„ØªÙ‡Ø§Ø¨ ØºÙŠØ± Ø§Ù„Ø³ØªÙŠØ±ÙˆÙŠØ¯ÙŠØ© ØªØ²ÙŠØ¯ Ù…Ù† ØªØ£Ø«ÙŠØ± Ø§Ù„ÙˆØ§Ø±ÙØ§Ø±ÙŠÙ† ÙˆØ®Ø·Ø± Ø§Ù„Ù†Ø²ÙŠÙ.',
    source: 'BNF',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'warfarin',
    drugBGeneric: 'metronidazole',
    severity: DrugInteractionSeverity.MODERATE,
    description: 'Metronidazole inhibits warfarin metabolism, increasing anticoagulant effect.',
    descriptionAr: 'Ø§Ù„Ù…ÙŠØªØ±ÙˆÙ†ÙŠØ¯Ø§Ø²ÙˆÙ„ ÙŠØ«Ø¨Ø· Ø§Ø³ØªÙ‚Ù„Ø§Ø¨ Ø§Ù„ÙˆØ§Ø±ÙØ§Ø±ÙŠÙ†ØŒ Ù…Ù…Ø§ ÙŠØ²ÙŠØ¯ Ù…Ù† ØªØ£Ø«ÙŠØ± Ù…Ø¶Ø§Ø¯ Ø§Ù„ØªØ®Ø«Ø±.',
    source: 'Micromedex',
    evidenceLevel: 'B',
  },

  // ============ Ø£Ø¯ÙˆÙŠØ© Ø§Ù„Ù‚Ù„Ø¨ (Cardiovascular) ============
  {
    drugAGeneric: 'sildenafil',
    drugBGeneric: 'nitroglycerin',
    severity: DrugInteractionSeverity.CONTRAINDICATED,
    description: 'Risk of life-threatening hypotension. Absolute contraindication.',
    descriptionAr: 'Ø®Ø·Ø± Ø§Ù†Ø®ÙØ§Ø¶ Ø¶ØºØ· Ø§Ù„Ø¯Ù… Ø§Ù„Ù…Ù‡Ø¯Ø¯ Ù„Ù„Ø­ÙŠØ§Ø©. Ù…ÙˆØ§Ù†Ø¹ Ø§Ø³ØªØ®Ø¯Ø§Ù… Ù…Ø·Ù„Ù‚Ø©.',
    recommendation: 'NEVER combine. Wait at least 24 hours between uses.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'sildenafil',
    drugBGeneric: 'isosorbide',
    severity: DrugInteractionSeverity.CONTRAINDICATED,
    description: 'Severe hypotension risk with nitrate combinations.',
    descriptionAr: 'Ø®Ø·Ø± Ø§Ù†Ø®ÙØ§Ø¶ Ø¶ØºØ· Ø§Ù„Ø¯Ù… Ø§Ù„Ø´Ø¯ÙŠØ¯ Ù…Ø¹ Ù…Ø¬Ù…ÙˆØ¹Ø§Øª Ø§Ù„Ù†ÙŠØªØ±Ø§Øª.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'digoxin',
    drugBGeneric: 'amiodarone',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Amiodarone increases digoxin levels, risk of toxicity.',
    descriptionAr: 'Ø§Ù„Ø£Ù…ÙŠÙˆØ¯Ø§Ø±ÙˆÙ† ÙŠØ±ÙØ¹ Ù…Ø³ØªÙˆÙŠØ§Øª Ø§Ù„Ø¯ÙŠØ¬ÙˆÙƒØ³ÙŠÙ†ØŒ Ø®Ø·Ø± Ø§Ù„Ø³Ù…ÙŠØ©.',
    recommendation: 'Reduce digoxin dose by 50% when starting amiodarone.',
    source: 'BNF',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'digoxin',
    drugBGeneric: 'verapamil',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Verapamil increases digoxin levels significantly.',
    descriptionAr: 'Ø§Ù„ÙÙŠØ±Ø§Ø¨Ø§Ù…ÙŠÙ„ ÙŠØ±ÙØ¹ Ù…Ø³ØªÙˆÙŠØ§Øª Ø§Ù„Ø¯ÙŠØ¬ÙˆÙƒØ³ÙŠÙ† Ø¨Ø´ÙƒÙ„ Ù…Ù„Ø­ÙˆØ¸.',
    source: 'Micromedex',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'atenolol',
    drugBGeneric: 'verapamil',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Risk of severe bradycardia, heart block, and hypotension.',
    descriptionAr: 'Ø®Ø·Ø± Ø¨Ø·Ø¡ Ø§Ù„Ù‚Ù„Ø¨ Ø§Ù„Ø´Ø¯ÙŠØ¯ØŒ Ø¥Ø­ØµØ§Ø± Ø§Ù„Ù‚Ù„Ø¨ØŒ ÙˆØ§Ù†Ø®ÙØ§Ø¶ Ø¶ØºØ· Ø§Ù„Ø¯Ù….',
    source: 'BNF',
    evidenceLevel: 'A',
  },

  // ============ Ø§Ù„Ø³ØªØ§ØªÙŠÙ†Ø§Øª (Statins) ============
  {
    drugAGeneric: 'simvastatin',
    drugBGeneric: 'clarithromycin',
    severity: DrugInteractionSeverity.CONTRAINDICATED,
    description: 'Risk of myopathy and rhabdomyolysis due to increased statin levels.',
    descriptionAr: 'Ø®Ø·Ø± Ø§Ø¹ØªÙ„Ø§Ù„ Ø§Ù„Ø¹Ø¶Ù„Ø§Øª ÙˆØ§Ù†Ø­Ù„Ø§Ù„ Ø§Ù„Ø¹Ø¶Ù„Ø§Øª Ø¨Ø³Ø¨Ø¨ Ø§Ø±ØªÙØ§Ø¹ Ù…Ø³ØªÙˆÙŠØ§Øª Ø§Ù„Ø³ØªØ§ØªÙŠÙ†.',
    recommendation: 'Suspend statin during clarithromycin course or use azithromycin.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'simvastatin',
    drugBGeneric: 'erythromycin',
    severity: DrugInteractionSeverity.CONTRAINDICATED,
    description: 'CYP3A4 inhibition increases simvastatin toxicity risk.',
    descriptionAr: 'ØªØ«Ø¨ÙŠØ· CYP3A4 ÙŠØ²ÙŠØ¯ Ù…Ù† Ø®Ø·Ø± Ø³Ù…ÙŠØ© Ø§Ù„Ø³ÙŠÙ…ÙØ§Ø³ØªØ§ØªÙŠÙ†.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'atorvastatin',
    drugBGeneric: 'gemfibrozil',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Increased risk of myopathy with statin-fibrate combination.',
    descriptionAr: 'Ø²ÙŠØ§Ø¯Ø© Ø®Ø·Ø± Ø§Ø¹ØªÙ„Ø§Ù„ Ø§Ù„Ø¹Ø¶Ù„Ø§Øª Ù…Ø¹ Ù…Ø²ÙŠØ¬ Ø§Ù„Ø³ØªØ§ØªÙŠÙ† ÙˆØ§Ù„ÙØ§ÙŠØ¨Ø±ÙŠØª.',
    source: 'FDA',
    evidenceLevel: 'A',
  },

  // ============ Ø§Ù„Ù…Ø¶Ø§Ø¯Ø§Øª Ø§Ù„Ø­ÙŠÙˆÙŠØ© (Antibiotics) ============
  {
    drugAGeneric: 'amoxicillin',
    drugBGeneric: 'allopurinol',
    severity: DrugInteractionSeverity.MODERATE,
    description: 'Increased risk of skin rash.',
    descriptionAr: 'Ø²ÙŠØ§Ø¯Ø© Ø®Ø·Ø± Ø§Ù„Ø·ÙØ­ Ø§Ù„Ø¬Ù„Ø¯ÙŠ.',
    source: 'BNF',
    evidenceLevel: 'B',
  },
  {
    drugAGeneric: 'ciprofloxacin',
    drugBGeneric: 'theophylline',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Ciprofloxacin inhibits theophylline metabolism, risk of toxicity.',
    descriptionAr: 'Ø§Ù„Ø³ÙŠØ¨Ø±ÙˆÙÙ„ÙˆÙƒØ³Ø§Ø³ÙŠÙ† ÙŠØ«Ø¨Ø· Ø§Ø³ØªÙ‚Ù„Ø§Ø¨ Ø§Ù„Ø«ÙŠÙˆÙÙŠÙ„ÙŠÙ†ØŒ Ø®Ø·Ø± Ø§Ù„Ø³Ù…ÙŠØ©.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'ciprofloxacin',
    drugBGeneric: 'tizanidine',
    severity: DrugInteractionSeverity.CONTRAINDICATED,
    description: 'Dramatic increase in tizanidine levels, causing severe hypotension and sedation.',
    descriptionAr: 'Ø²ÙŠØ§Ø¯Ø© ÙƒØ¨ÙŠØ±Ø© ÙÙŠ Ù…Ø³ØªÙˆÙŠØ§Øª Ø§Ù„ØªÙŠØ²Ø§Ù†ÙŠØ¯ÙŠÙ†ØŒ Ù…Ø³Ø¨Ø¨Ø© Ø§Ù†Ø®ÙØ§Ø¶ Ø¶ØºØ· Ø§Ù„Ø¯Ù… Ø§Ù„Ø´Ø¯ÙŠØ¯ ÙˆØ§Ù„ØªØ®Ø¯ÙŠØ±.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'metronidazole',
    drugBGeneric: 'alcohol',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Disulfiram-like reaction: nausea, vomiting, flushing, headache.',
    descriptionAr: 'ØªÙØ§Ø¹Ù„ Ø´Ø¨ÙŠÙ‡ Ø¨Ø§Ù„Ø¯ÙŠØ³Ù„ÙÙŠØ±Ø§Ù…: ØºØ«ÙŠØ§Ù†ØŒ Ù‚ÙŠØ¡ØŒ Ø§Ø­Ù…Ø±Ø§Ø±ØŒ ØµØ¯Ø§Ø¹.',
    recommendation: 'Avoid alcohol during and 48 hours after metronidazole.',
    source: 'BNF',
    evidenceLevel: 'A',
  },

  // ============ Ø£Ø¯ÙˆÙŠØ© Ø§Ù„Ø³ÙƒØ±ÙŠ (Diabetes) ============
  {
    drugAGeneric: 'metformin',
    drugBGeneric: 'contrast media',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Risk of lactic acidosis with iodinated contrast.',
    descriptionAr: 'Ø®Ø·Ø± Ø§Ù„Ø­Ù…Ø§Ø¶ Ø§Ù„Ù„Ø¨Ù†ÙŠ Ù…Ø¹ Ù…Ø§Ø¯Ø© Ø§Ù„ØªØ¨Ø§ÙŠÙ† Ø§Ù„ÙŠÙˆØ¯ÙŠØ©.',
    recommendation: 'Hold metformin for 48 hours after contrast administration.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'glibenclamide',
    drugBGeneric: 'fluconazole',
    severity: DrugInteractionSeverity.MODERATE,
    description: 'Fluconazole increases sulfonylurea levels, risk of hypoglycemia.',
    descriptionAr: 'Ø§Ù„ÙÙ„ÙˆÙƒÙˆÙ†Ø§Ø²ÙˆÙ„ ÙŠØ±ÙØ¹ Ù…Ø³ØªÙˆÙŠØ§Øª Ø§Ù„Ø³Ù„ÙÙˆÙ†ÙŠÙ„ÙŠÙˆØ±ÙŠØ§ØŒ Ø®Ø·Ø± Ù†Ù‚Øµ Ø§Ù„Ø³ÙƒØ±.',
    source: 'Micromedex',
    evidenceLevel: 'B',
  },

  // ============ Ù…Ø¶Ø§Ø¯Ø§Øª Ø§Ù„ØªØ®Ø«Ø± Ø§Ù„Ø¬Ø¯ÙŠØ¯Ø© (DOACs) ============
  {
    drugAGeneric: 'rivaroxaban',
    drugBGeneric: 'ketoconazole',
    severity: DrugInteractionSeverity.CONTRAINDICATED,
    description: 'Strong CYP3A4 and P-gp inhibition dramatically increases bleeding risk.',
    descriptionAr: 'Ø§Ù„ØªØ«Ø¨ÙŠØ· Ø§Ù„Ù‚ÙˆÙŠ Ù„Ù€ CYP3A4 Ùˆ P-gp ÙŠØ²ÙŠØ¯ Ø¨Ø´ÙƒÙ„ ÙƒØ¨ÙŠØ± Ù…Ù† Ø®Ø·Ø± Ø§Ù„Ù†Ø²ÙŠÙ.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'apixaban',
    drugBGeneric: 'rifampicin',
    severity: DrugInteractionSeverity.CONTRAINDICATED,
    description: 'Rifampicin significantly reduces apixaban levels, loss of efficacy.',
    descriptionAr: 'Ø§Ù„Ø±ÙŠÙØ§Ù…Ø¨ÙŠØ³ÙŠÙ† ÙŠÙ‚Ù„Ù„ Ø¨Ø´ÙƒÙ„ ÙƒØ¨ÙŠØ± Ù…Ù† Ù…Ø³ØªÙˆÙŠØ§Øª Ø§Ù„Ø£Ø¨ÙŠÙƒØ³Ø§Ø¨Ø§Ù†ØŒ ÙÙ‚Ø¯Ø§Ù† Ø§Ù„ÙØ¹Ø§Ù„ÙŠØ©.',
    source: 'FDA',
    evidenceLevel: 'A',
  },

  // ============ Ù…Ø¶Ø§Ø¯Ø§Øª Ø§Ù„Ø§ÙƒØªØ¦Ø§Ø¨ (Antidepressants) ============
  {
    drugAGeneric: 'fluoxetine',
    drugBGeneric: 'tramadol',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Risk of serotonin syndrome and seizures.',
    descriptionAr: 'Ø®Ø·Ø± Ù…ØªÙ„Ø§Ø²Ù…Ø© Ø§Ù„Ø³ÙŠØ±ÙˆØªÙˆÙ†ÙŠÙ† ÙˆØ§Ù„Ù†ÙˆØ¨Ø§Øª.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'sertraline',
    drugBGeneric: 'tramadol',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Serotonin syndrome risk with SSRI-tramadol combination.',
    descriptionAr: 'Ø®Ø·Ø± Ù…ØªÙ„Ø§Ø²Ù…Ø© Ø§Ù„Ø³ÙŠØ±ÙˆØªÙˆÙ†ÙŠÙ† Ù…Ø¹ Ù…Ø²ÙŠØ¬ SSRI ÙˆØ§Ù„ØªØ±Ø§Ù…Ø§Ø¯ÙˆÙ„.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'fluoxetine',
    drugBGeneric: 'monoamine oxidase inhibitor',
    severity: DrugInteractionSeverity.CONTRAINDICATED,
    description: 'Fatal serotonin syndrome. Absolute contraindication.',
    descriptionAr: 'Ù…ØªÙ„Ø§Ø²Ù…Ø© Ø§Ù„Ø³ÙŠØ±ÙˆØªÙˆÙ†ÙŠÙ† Ø§Ù„Ù‚Ø§ØªÙ„Ø©. Ù…ÙˆØ§Ù†Ø¹ Ø§Ø³ØªØ®Ø¯Ø§Ù… Ù…Ø·Ù„Ù‚Ø©.',
    recommendation: 'Allow 5 weeks washout between fluoxetine and MAOIs.',
    source: 'FDA',
    evidenceLevel: 'A',
  },

  // ============ Ø§Ù„Ù…Ø³ÙƒÙ†Ø§Øª (Analgesics) ============
  {
    drugAGeneric: 'codeine',
    drugBGeneric: 'paroxetine',
    severity: DrugInteractionSeverity.MODERATE,
    description: 'Paroxetine inhibits codeine conversion to morphine, reducing efficacy.',
    descriptionAr: 'Ø§Ù„Ø¨Ø§Ø±ÙˆÙƒØ³ØªÙŠÙ† ÙŠØ«Ø¨Ø· ØªØ­ÙˆÙŠÙ„ Ø§Ù„ÙƒÙˆØ¯Ø§ÙŠÙŠÙ† Ø¥Ù„Ù‰ Ø§Ù„Ù…ÙˆØ±ÙÙŠÙ†ØŒ Ù…Ù…Ø§ ÙŠÙ‚Ù„Ù„ Ø§Ù„ÙØ¹Ø§Ù„ÙŠØ©.',
    source: 'Micromedex',
    evidenceLevel: 'B',
  },
  {
    drugAGeneric: 'morphine',
    drugBGeneric: 'benzodiazepine',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Risk of profound sedation, respiratory depression, coma, and death.',
    descriptionAr: 'Ø®Ø·Ø± Ø§Ù„ØªØ®Ø¯ÙŠØ± Ø§Ù„Ø¹Ù…ÙŠÙ‚ØŒ ØªØ«Ø¨ÙŠØ· Ø§Ù„ØªÙ†ÙØ³ØŒ Ø§Ù„ØºÙŠØ¨ÙˆØ¨Ø©ØŒ ÙˆØ§Ù„ÙˆÙØ§Ø©.',
    source: 'FDA Black Box Warning',
    evidenceLevel: 'A',
  },

  // ============ Ø£Ø¯ÙˆÙŠØ© Ø§Ù„ØµØ±Ø¹ (Antiepileptics) ============
  {
    drugAGeneric: 'carbamazepine',
    drugBGeneric: 'oral contraceptive',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Carbamazepine induces metabolism of hormonal contraceptives.',
    descriptionAr: 'Ø§Ù„ÙƒØ§Ø±Ø¨Ø§Ù…Ø§Ø²ÙŠØ¨ÙŠÙ† ÙŠØ­ÙØ² Ø§Ø³ØªÙ‚Ù„Ø§Ø¨ Ù…ÙˆØ§Ù†Ø¹ Ø§Ù„Ø­Ù…Ù„ Ø§Ù„Ù‡Ø±Ù…ÙˆÙ†ÙŠØ©.',
    recommendation: 'Use alternative contraception or higher dose pills.',
    source: 'BNF',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'phenytoin',
    drugBGeneric: 'oral contraceptive',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Phenytoin reduces contraceptive efficacy.',
    descriptionAr: 'Ø§Ù„ÙÙŠÙ†ÙŠØªÙˆÙŠÙ† ÙŠÙ‚Ù„Ù„ Ù…Ù† ÙØ¹Ø§Ù„ÙŠØ© Ù…ÙˆØ§Ù†Ø¹ Ø§Ù„Ø­Ù…Ù„.',
    source: 'BNF',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'valproic acid',
    drugBGeneric: 'lamotrigine',
    severity: DrugInteractionSeverity.MODERATE,
    description: 'Valproate doubles lamotrigine levels, requiring dose adjustment.',
    descriptionAr: 'Ø§Ù„ÙØ§Ù„Ø¨Ø±ÙˆØ§Øª ÙŠØ¶Ø§Ø¹Ù Ù…Ø³ØªÙˆÙŠØ§Øª Ø§Ù„Ù„Ø§Ù…ÙˆØªØ±ÙŠØ¬ÙŠÙ†ØŒ Ù…Ù…Ø§ ÙŠØªØ·Ù„Ø¨ ØªØ¹Ø¯ÙŠÙ„ Ø§Ù„Ø¬Ø±Ø¹Ø©.',
    recommendation: 'Start lamotrigine at lower dose and titrate slowly.',
    source: 'FDA',
    evidenceLevel: 'A',
  },

  // ============ Ù…Ø«Ø¨Ø·Ø§Øª Ø§Ù„Ù…Ù†Ø§Ø¹Ø© (Immunosuppressants) ============
  {
    drugAGeneric: 'cyclosporine',
    drugBGeneric: 'potassium supplement',
    severity: DrugInteractionSeverity.MODERATE,
    description: 'Risk of severe hyperkalemia.',
    descriptionAr: 'Ø®Ø·Ø± Ø§Ø±ØªÙØ§Ø¹ Ø§Ù„Ø¨ÙˆØªØ§Ø³ÙŠÙˆÙ… Ø§Ù„Ø´Ø¯ÙŠØ¯.',
    source: 'Micromedex',
    evidenceLevel: 'B',
  },
  {
    drugAGeneric: 'tacrolimus',
    drugBGeneric: 'fluconazole',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Fluconazole significantly increases tacrolimus levels.',
    descriptionAr: 'Ø§Ù„ÙÙ„ÙˆÙƒÙˆÙ†Ø§Ø²ÙˆÙ„ ÙŠØ±ÙØ¹ Ù…Ø³ØªÙˆÙŠØ§Øª Ø§Ù„ØªØ§ÙƒØ±ÙˆÙ„ÙŠÙ…ÙˆØ³ Ø¨Ø´ÙƒÙ„ ÙƒØ¨ÙŠØ±.',
    recommendation: 'Monitor tacrolimus levels closely, consider dose reduction.',
    source: 'FDA',
    evidenceLevel: 'A',
  },

  // ============ Ø£Ø¯ÙˆÙŠØ© Ø£Ø®Ø±Ù‰ Ù…Ù‡Ù…Ø© ============
  {
    drugAGeneric: 'lithium',
    drugBGeneric: 'ibuprofen',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'NSAIDs increase lithium levels, risk of toxicity.',
    descriptionAr: 'Ù…Ø¶Ø§Ø¯Ø§Øª Ø§Ù„Ø§Ù„ØªÙ‡Ø§Ø¨ ØºÙŠØ± Ø§Ù„Ø³ØªÙŠØ±ÙˆÙŠØ¯ÙŠØ© ØªØ±ÙØ¹ Ù…Ø³ØªÙˆÙŠØ§Øª Ø§Ù„Ù„ÙŠØ«ÙŠÙˆÙ…ØŒ Ø®Ø·Ø± Ø§Ù„Ø³Ù…ÙŠØ©.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'lithium',
    drugBGeneric: 'ace inhibitor',
    severity: DrugInteractionSeverity.MODERATE,
    description: 'ACE inhibitors may increase lithium levels.',
    descriptionAr: 'Ù…Ø«Ø¨Ø·Ø§Øª Ø§Ù„Ø¥Ù†Ø²ÙŠÙ… Ø§Ù„Ù…Ø­ÙˆÙ„ Ù„Ù„Ø£Ù†Ø¬ÙŠÙˆØªÙ†Ø³ÙŠÙ† Ù‚Ø¯ ØªØ±ÙØ¹ Ù…Ø³ØªÙˆÙŠØ§Øª Ø§Ù„Ù„ÙŠØ«ÙŠÙˆÙ….',
    source: 'BNF',
    evidenceLevel: 'B',
  },
  {
    drugAGeneric: 'potassium supplement',
    drugBGeneric: 'spironolactone',
    severity: DrugInteractionSeverity.SEVERE,
    description: 'Risk of life-threatening hyperkalemia.',
    descriptionAr: 'Ø®Ø·Ø± Ø§Ø±ØªÙØ§Ø¹ Ø§Ù„Ø¨ÙˆØªØ§Ø³ÙŠÙˆÙ… Ø§Ù„Ù…Ù‡Ø¯Ø¯ Ù„Ù„Ø­ÙŠØ§Ø©.',
    source: 'FDA',
    evidenceLevel: 'A',
  },
  {
    drugAGeneric: 'clopidogrel',
    drugBGeneric: 'omeprazole',
    severity: DrugInteractionSeverity.MODERATE,
    description: 'Omeprazole may reduce clopidogrel antiplatelet effect.',
    descriptionAr: 'Ø§Ù„Ø£ÙˆÙ…ÙŠØ¨Ø±Ø§Ø²ÙˆÙ„ Ù‚Ø¯ ÙŠÙ‚Ù„Ù„ Ù…Ù† ØªØ£Ø«ÙŠØ± Ø§Ù„ÙƒÙ„ÙˆØ¨ÙŠØ¯ÙˆØ¬Ø±ÙŠÙ„ Ø§Ù„Ù…Ø¶Ø§Ø¯ Ù„Ù„ØµÙÙŠØ­Ø§Øª.',
    recommendation: 'Consider pantoprazole as PPI alternative.',
    source: 'FDA',
    evidenceLevel: 'B',
  },
];

// ======================== Ø§Ù„Ù‚ÙŠÙ… Ø§Ù„Ø­Ø±Ø¬Ø© Ù„Ù„Ù…Ø®ØªØ¨Ø± ========================

const LAB_CRITICAL_VALUES = [
  { labTestCode: 'K', labTestName: 'Potassium', criticalLow: 2.5, criticalHigh: 6.5, panicLow: 2.0, panicHigh: 7.0, unit: 'mEq/L', action: 'Notify physician STAT' },
  { labTestCode: 'NA', labTestName: 'Sodium', criticalLow: 120, criticalHigh: 160, panicLow: 115, panicHigh: 165, unit: 'mEq/L', action: 'Notify physician STAT' },
  { labTestCode: 'GLU', labTestName: 'Glucose', criticalLow: 40, criticalHigh: 450, panicLow: 30, panicHigh: 600, unit: 'mg/dL', action: 'Immediate intervention' },
  { labTestCode: 'HGB', labTestName: 'Hemoglobin', criticalLow: 5, criticalHigh: 20, panicLow: 4, panicHigh: 22, unit: 'g/dL', action: 'Consider transfusion' },
  { labTestCode: 'PLT', labTestName: 'Platelets', criticalLow: 20, criticalHigh: 1000, panicLow: 10, panicHigh: 1200, unit: 'x10Â³/ÂµL', action: 'Bleeding precautions' },
  { labTestCode: 'WBC', labTestName: 'White Blood Cells', criticalLow: 1.0, criticalHigh: 50, panicLow: 0.5, panicHigh: 100, unit: 'x10Â³/ÂµL', action: 'Infection control' },
  { labTestCode: 'CREAT', labTestName: 'Creatinine', criticalLow: null, criticalHigh: 10, panicLow: null, panicHigh: 15, unit: 'mg/dL', action: 'Nephrology consult' },
  { labTestCode: 'BUN', labTestName: 'Blood Urea Nitrogen', criticalLow: null, criticalHigh: 100, panicLow: null, panicHigh: 150, unit: 'mg/dL', action: 'Renal assessment' },
  { labTestCode: 'CA', labTestName: 'Calcium', criticalLow: 6.0, criticalHigh: 13, panicLow: 5.5, panicHigh: 14, unit: 'mg/dL', action: 'ECG monitoring' },
  { labTestCode: 'MG', labTestName: 'Magnesium', criticalLow: 1.0, criticalHigh: 5.0, panicLow: 0.8, panicHigh: 6.0, unit: 'mg/dL', action: 'Cardiac monitoring' },
  { labTestCode: 'INR', labTestName: 'INR', criticalLow: null, criticalHigh: 5.0, panicLow: null, panicHigh: 8.0, unit: '', action: 'Bleeding risk assessment' },
  { labTestCode: 'TROP', labTestName: 'Troponin', criticalLow: null, criticalHigh: 0.04, panicLow: null, panicHigh: 0.1, unit: 'ng/mL', action: 'Cardiology STAT' },
];

// ======================== Ø§Ù„Ù‚ÙŠÙ… Ø§Ù„Ø­Ø±Ø¬Ø© Ù„Ù„Ø¹Ù„Ø§Ù…Ø§Øª Ø§Ù„Ø­ÙŠÙˆÙŠØ© ========================

const VITAL_CRITICAL_VALUES = [
  { vitalType: 'HR', vitalName: 'Heart Rate', criticalLow: 40, criticalHigh: 150, unit: 'bpm', action: 'ECG STAT', ageGroup: 'ADULT' },
  { vitalType: 'HR', vitalName: 'Heart Rate (Pediatric)', criticalLow: 60, criticalHigh: 180, unit: 'bpm', action: 'Pediatric assessment', ageGroup: 'CHILD' },
  { vitalType: 'BP_SYS', vitalName: 'Systolic BP', criticalLow: 70, criticalHigh: 200, unit: 'mmHg', action: 'Immediate assessment', ageGroup: 'ADULT' },
  { vitalType: 'BP_DIA', vitalName: 'Diastolic BP', criticalLow: 40, criticalHigh: 120, unit: 'mmHg', action: 'Immediate assessment', ageGroup: 'ADULT' },
  { vitalType: 'TEMP', vitalName: 'Temperature', criticalLow: 35, criticalHigh: 40, unit: 'Â°C', action: 'Sepsis protocol', ageGroup: null },
  { vitalType: 'SPO2', vitalName: 'Oxygen Saturation', criticalLow: 88, criticalHigh: null, unit: '%', action: 'Oxygen therapy STAT', ageGroup: 'ADULT' },
  { vitalType: 'RR', vitalName: 'Respiratory Rate', criticalLow: 8, criticalHigh: 30, unit: '/min', action: 'Respiratory assessment', ageGroup: 'ADULT' },
];

// ======================== Main Seed Function ========================

export async function seedCDSS() {
  console.log('ðŸ¥ Seeding CDSS Data...');

  // 1. Drug Interactions
  console.log('ðŸ’Š Seeding Drug Interactions...');
  for (const interaction of DRUG_INTERACTIONS) {
    await prisma.drugInteraction.upsert({
      where: {
        drugAGeneric_drugBGeneric: {
          drugAGeneric: interaction.drugAGeneric.toLowerCase(),
          drugBGeneric: interaction.drugBGeneric.toLowerCase(),
        },
      },
      update: interaction,
      create: {
        ...interaction,
        drugAGeneric: interaction.drugAGeneric.toLowerCase(),
        drugBGeneric: interaction.drugBGeneric.toLowerCase(),
      },
    });
  }
  console.log(`   âœ… ${DRUG_INTERACTIONS.length} drug interactions seeded`);

  // 2. Lab Critical Values - Ø§Ø³ØªØ®Ø¯Ø§Ù… deleteMany/createMany Ù„ØªØ¬Ù†Ø¨ Ù…Ø´Ø§ÙƒÙ„ null ÙÙŠ unique constraint
  console.log('ðŸ§ª Seeding Lab Critical Values...');
  // Ø­Ø°Ù Ø§Ù„Ù‚ÙŠÙ… Ø§Ù„Ù‚Ø¯ÙŠÙ…Ø© Ø£ÙˆÙ„Ø§Ù‹
  await prisma.labCriticalValue.deleteMany({});
  // Ø¥Ù†Ø´Ø§Ø¡ Ø§Ù„Ù‚ÙŠÙ… Ø§Ù„Ø¬Ø¯ÙŠØ¯Ø©
  await prisma.labCriticalValue.createMany({
    data: LAB_CRITICAL_VALUES.map(lab => ({
      ...lab,
      ageGroup: undefined, // null = undefined for optional fields
      gender: undefined,
    })),
    skipDuplicates: true,
  });
  console.log(`   âœ… ${LAB_CRITICAL_VALUES.length} lab critical values seeded`);

  // 3. Vital Critical Values
  console.log('â¤ï¸ Seeding Vital Critical Values...');
  // Ø­Ø°Ù Ø§Ù„Ù‚ÙŠÙ… Ø§Ù„Ù‚Ø¯ÙŠÙ…Ø© Ø£ÙˆÙ„Ø§Ù‹
  await prisma.vitalCriticalValue.deleteMany({});
  // Ø¥Ù†Ø´Ø§Ø¡ Ø§Ù„Ù‚ÙŠÙ… Ø§Ù„Ø¬Ø¯ÙŠØ¯Ø©
  await prisma.vitalCriticalValue.createMany({
    data: VITAL_CRITICAL_VALUES.map(vital => ({
      ...vital,
      ageGroup: vital.ageGroup ?? undefined, // ØªØ­ÙˆÙŠÙ„ null Ø¥Ù„Ù‰ undefined
    })),
    skipDuplicates: true,
  });
  console.log(`   âœ… ${VITAL_CRITICAL_VALUES.length} vital critical values seeded`);

  console.log('ðŸŽ‰ CDSS Seeding Complete!');
}

// Run if executed directly
if (require.main === module) {
  seedCDSS()
    .catch(console.error)
    .finally(() => prisma.$disconnect());
}
